Stromal CAR-T: target is the FAPa+ synovial fibroblast Mouse arthritis, CAR-T IV at 1st flare Swelling AUC lower over 3 episodes, all p<0.001 Lining architecture restored Preclinical. FAPa sits outside the joint, off-target depletion decides the path Adam Croft @RheumNow #ACR26 https://t.co/vufSwu4gKU

#ACR26 @RheumNow Ab#2824 FORWARD - type 2 SLE sx (nociplastic, non-inflamm) Scored Inflammatory sx score (SLAQ), Fibromyalgia survey score -59% had high FM score -Opioid use in combined inflamm/FM group -FM scores did not follow inflamm improv 1 in 6 had peristent nociplastic sx https://t.co/lNwhz4uunA

Not just another ‘JAK’ Ph3 #RCT in active #RA 1 #bDMARD-IR 24w #Gyrocotinib #JAK1/Tyk2 vs Tofacitinib #JAK1 Gyro was superior #ACR50 73% vs 49.5% Replicating Ph2 results Other outcomes gyro>tofa Similar safety ?will results be replicated beyond China #LB21 #ACR26 @RheumNow https://t.co/ggN6X1kfED

#ACR26 @RheumNow Ab#2823 CPIRA (Centralized Pain in RA) - RA observ cohort, change of DMARD at entry, 12 wk 1/4 pts = symptom-dominant phenotype w less inflamm, highest BMI, TJC, FSQ Symptoms do not align with inflamm Distinct profiles remain apparent at 12 wks despite new Rx https://t.co/92EK2P568s

Wondering what you would use cheap generic tofacitinib for? Well look no further. Find someone who would rather take steroids over tofa for their PMR & I will take them to meet my patients. ITTG PMR study (open label RCT, n=104) same people as EAST PMR ABST2106 #ACR26 @RheumNow https://t.co/VQh1zprZbC

Maybe a slightly gentler incline than bimekizumab & maybe a bit closer to guselkumab, but the new oral IL-23i icotrokinra works in PsA. It's great to have a potential oral PsA option that is very safe but also has the required modern standard for skin ABSTLB12 #ACR26 @RheumNow https://t.co/Duofo3ZzZ7

#ACR26 @RheumNow A#1822 B/L Nociplastic Pain Assoc w Worse Chronic Low Back Pain (CLBP) Fxn comeBACK - prospective, longitudinal cohort of CLBP Evaluate absent/possible/probable nociplastic pain Absent - improvement of Phys fxn over time, possilbe - stable, probable-show decline https://t.co/9m1NM6t6N3

Rapid manufacture zola-cel CAR-T appears to be back on. The SLE patients in the ph1 Breakfree-1 study did just fine for a long time, thank you very much. Conventional CAR-T is not sustainable on the scale we might like, so on with ph2 & watch closely. ABSTLB04 #ACR26 @RheumNow https://t.co/lYWpheX3Cj

In amongst new meds in Sjogren's, those looking at LEF/HCQ have kept at it. Further French data shows both LEF/HCQ & MMF/HCQ benefit after 24w Rx. While some will definitely need new SjD therapies, some will be just fine on Rx we can get readily now. ABSTLB15 #ACR26 @RheumNow https://t.co/erAgjRPWpL

Worried about biologics in RA patients who have had cancer? Spanish registry data n=728 11022pt-y bDMARDs across classes were no different (trend better) Always hard to interpret this data type/context but every sign has been reassuring for bDMARDs ABST2409 #ACR26 @RheumNow https://t.co/RYMoYK1WKU

Way et al. Predicting response to immunomodulators in RA-ILD. Using UIP to predict non response is poor! AUC 0.477. Multivariable model with radiology + clinical features better but still AUC 0.629. Maybe all RA-ILD deserves a trial of immunomodulator? @RheumNow #ACR26 Abstr#2688 https://t.co/KSmzAXXpcP

Aguilar-Coll et al. Survival patterns by radiologic phenotype in RA-ILD. 69 patients. UIP worse than NSIP, which we knew. But OP same as UIP!? And NSIP+OP worst of all!? Needs further study! @RheumNow #ACR26 Abstr#2435 https://t.co/z4JgLc9xTZ